Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients

Summary

The purpose of this study is to evaluate the real-world efficacy and safety of ixazomib, lenalidomide, or ixazomib in combination with lenalidomide as maintenance therapy in patients with newly diagnosed multiple myeloma in China.

Conditions

• Multiple Myeloma

Interventions

DRUG

Ixazomib

the ixazomib group uses ixazomib as the comparator group, the combination group receives both lenalidomide and ixazomib as the experimental group

DRUG

Lenalidomide

the lenalidomide group uses lenalidomide as comparitor group and the combination group receives both lenalidomide and ixazomib

Sponsors & Collaborators

• Peking University Third Hospital

  collaborator OTHER

• Beijing Jishuitan Hospital

  collaborator OTHER

• Beijing Chao Yang Hospital

  collaborator OTHER

• Xuanwu Hospital, Beijing

  collaborator OTHER

• Peking University First Hospital

  collaborator OTHER

• Jilin Provincial Tumor Hospital

  collaborator OTHER

• Second Hospital of Shanxi Medical University

  collaborator OTHER

• The First Affiliated Hospital of Shanxi Medical University

  collaborator OTHER

• Tianjin Medical University General Hospital

  collaborator OTHER

• The First Affiliated Hospital of Anhui Medical University

  collaborator OTHER

• Shanxi Bethune Hospital

  collaborator OTHER

• Beijing Hospital

  collaborator OTHER_GOV

• Peking Union Medical College Hospital

  lead OTHER

Principal Investigators

• Junling Zhuang, MD · Peking Union Medical College, department of hematology

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-09-24

Primary Completion

2024-06-30

Completion

2024-06-30

FDA Drug

Yes

Countries

• China

Study Locations